Emerging lipid-lowering drugs: squalene synthase inhibitors

By Elsayed Raghda K   Evans Jeffery D  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 309-322

Informa Healthcare

Access to resources Recommend Favorite

Squalene Synthase Inhibitors: Clinical Pharmacology and Cholesterol-Lowering Potential

By Charlton-Menys Valentine   Durrington Paul N.  

Drugs, Vol. 67, Iss. 1, 2007-01 ,pp. : 11-16

Adis International

Access to resources Recommend Favorite

Squalene Synthase Inhibitors: An Update on the Search for New Antihyperlipidemic and Antiatherosclerotic Agents

By  

Current Medicinal Chemistry, Vol. 18, Iss. 29, 2011-10 ,pp. : 4418-4439

Bentham Science Publishers

Access to resources Recommend Favorite

EP2300 Compounds: Focusing on the Antiatherosclerotic Properties of Squalene Synthase Inhibitors

By  

Current Pharmaceutical Design, Vol. 15, Iss. 27, 2009-09 ,pp. : 3167-3178

Bentham Science Publishers

Access to resources Recommend Favorite

Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism

By Hiyoshi H.   Yanagimachi M.   Ito M.   Saeki T.   Yoshida I.   Okada T.   Ikuta H.   Shinmyo D.   Tanaka K.   Kurusu N.   Tanaka H.  

European Journal of Pharmacology, Vol. 431, Iss. 3, 2001-11 ,pp. : 345-352

Elsevier

Access to resources Recommend Favorite